ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)
  Report
Real-time Estimate Cboe BZX  -  12:45 2022-07-06 pm EDT
1.755 USD   +5.72%
11:08aEuropean ADRs Move Lower in Wednesday Trading
MT
07/05European ADRs Plunge in Tuesday Trading
MT
06/28European ADRs Nudge Lower in Tuesday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
1.71(c) 1.7(c) 1.65(c) 1.66(c) 1.76 Last
188 431 331 098 403 748 873 296 159 599 Volume
-1.72% -0.58% -2.94% +0.61% +6.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 25,8 M - -
Net income 2022 -189 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,48x
Yield 2022 -
Sales 2023 71,3 M - -
Net income 2023 -162 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,25x
Yield 2023 -
Capitalization 269 M 269 M -
Capi. / Sales 2022 10,4x
Capi. / Sales 2023 3,77x
Nbr of Employees 494
Free-Float 6,95%
More Financials
Company
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and have reported clinical responses (per RECIST 1.1) in seven solid tumor indications. Its platform enables to identify cancer targets, find and develop cell therapy candidates active against those targets and produce... 
More about the company
Ratings of Adaptimmune Therapeutics plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ADAPTIMMUNE THERAPEUTICS PLC
11:08aEuropean ADRs Move Lower in Wednesday Trading
MT
07/05European ADRs Plunge in Tuesday Trading
MT
06/28European ADRs Nudge Lower in Tuesday Trading
MT
06/22European ADRs Nudge Higher in Wednesday Trading
MT
06/17European ADRs Move Lower in Friday Trading
MT
06/16European ADRs Fall Sharply in Thursday Trading
MT
06/15ADAPTIMMUNE THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial State..
AQ
06/15European ADRs Move Higher in Wednesday Trading
MT
06/14European ADRs Move Lower in Tuesday Trading
MT
06/08European ADRs Move Lower in Wednesday Trading
MT
06/03European ADRs Move Lower in Friday Trading
MT
06/02European ADRs Nudge Lower in Thursday Trading
MT
05/25ADAPTIMMUNE THERAPEUTICS : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
05/25ADAPTIMMUNE THERAPEUTICS PLC : Submission of Matters to a Vote of Security Holders (form 8..
AQ
05/23European ADRs Climb Sharply Higher in Monday Trading
MT
More news
News in other languages on ADAPTIMMUNE THERAPEUTICS PLC
11:08aLes ADR européens sont en baisse mercredi
07/05Les ADR européens plongent dans les échanges de mardi
06/28Les ADR européens en baisse dans les échanges de mardi
06/22Les ADR européens en hausse dans les échanges de mercredi
06/17Les ADR européens sont en baisse vendredi
More news
Analyst Recommendations on ADAPTIMMUNE THERAPEUTICS PLC
More recommendations
Chart ADAPTIMMUNE THERAPEUTICS PLC
Duration : Period :
Adaptimmune Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIMMUNE THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Last Close Price 1,66 $
Average target price 5,80 $
Spread / Average Target 249%
EPS Revisions
Managers and Directors
Adrian Rawcliffe Chief Executive Officer & Director
Gavin Wood Chief Financial Officer
David M. Mott Chairman
Joanna Brewer Chief Scientific Officer
William C. Bertrand Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ADAPTIMMUNE THERAPEUTICS PLC-55.73%269
GILEAD SCIENCES, INC.-14.14%78 194
VERTEX PHARMACEUTICALS31.59%73 908
REGENERON PHARMACEUTICALS, INC.-5.54%64 277
WUXI APPTEC CO., LTD.-4.30%49 127
BIONTECH SE-37.54%39 133